Imatinib mesylate for the treatment of pulmonary arterial hypertension

Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension

(2013) Gérald Simonneau   ANNALS OF INTERNAL MEDICINE

Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia

(2011) D. Dumitrescu et al.   EUROPEAN RESPIRATORY JOURNAL

Disruption of Platelet-Derived Growth Factor–Dependent Phosphatidylinositol 3-Kinase and Phospholipase Cγ 1 Activity Abolishes Vascular Smooth Muscle Cell Proliferation and Migration and Attenuates Neointima Formation In Vivo

(2011) Evren Caglayan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

(2011) Jan K Hennigs et al.   BMC Pulmonary Medicine

Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension

(2010) Emilia Falcetti et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy

(2010) Hossein A. Ghofrani et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Hypoxia Enhances Platelet-derived Growth Factor Signaling in the Pulmonary Vasculature by Down-Regulation of Protein Tyrosine Phosphatases

(2010) Henrik ten Freyhaus et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

(2010) Wei-Gang Tong et al.   CANCER

Predicting Survival in Pulmonary Arterial Hypertension

(2010) Raymond L. Benza et al.   CIRCULATION

Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era

(2010) Marc Humbert et al.   CIRCULATION

Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics

(2010) Hui Cheng et al.   CIRCULATION RESEARCH

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses

(2010) N. Galie et al.   EUROPEAN HEART JOURNAL

Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension

(2010) N. Gambaryan et al.   EUROPEAN RESPIRATORY JOURNAL

PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue

(2010) Marius Vantler et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension

(2009) Aiko Ogawa et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension

(2009) Bhola Kumar Dahal et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Tadalafil Therapy for Pulmonary Arterial Hypertension

(2009) Nazzareno Galiè et al.   CIRCULATION

Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension

(2009) Henrik ten Freyhaus et al.   Clinical Research in Cardiology

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

(2009) N. Galie et al.   EUROPEAN HEART JOURNAL

Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)

(2009) et al.   EUROPEAN HEART JOURNAL

Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents

(2009) Mohamed Izikki et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension

(2009) Ronald J. Oudiz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

(2009) Vallerie V. McLaughlin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Development and Pathology of Pulmonary Hypertension

(2009) Rubin M. Tuder et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genetics and Genomics of Pulmonary Arterial Hypertension

(2009) Rajiv D. Machado et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension

(2009) Robyn J. Barst et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cellular and Molecular Basis of Pulmonary Arterial Hypertension

(2009) Nicholas W. Morrell et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Diagnosis and Assessment of Pulmonary Arterial Hypertension

(2009) David B. Badesch et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inflammation, Growth Factors, and Pulmonary Vascular Remodeling

(2009) Paul M. Hassoun et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updated Clinical Classification of Pulmonary Hypertension

(2009) Gérald Simonneau et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension

(2008) Frédéric Perros et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient

(2008) D Mattei et al.   BONE MARROW TRANSPLANTATION

Platelet-Derived Growth Factor Receptor β Signaling Is Required for Efficient Epicardial Cell Migration and Development of Two Distinct Coronary Vascular Smooth Muscle Cell Populations

(2008) Amy M. Mellgren et al.   CIRCULATION RESEARCH

Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia

(2008) Walid Rasheed et al.   LEUKEMIA RESEARCH